Monoclonal Antibodies as Therapeutic Agents

作者: Manzoor M. Khan

DOI: 10.1007/978-0-387-77976-8_5

关键词:

摘要: Monoclonal antibodies are effective targeted therapeutic agents. The high specificity of the makes them ideal to reach their intended target and thus is useful treat a variety disease states. This chapter begins with an explanation methods which used propagate isolate monoclonal antibodies. There description hybridoma technology, CDR grafting, phage display technology. These techniques develop various antibodies, including chimeric, humanized, human followed by specific as drugs diseases autoimmune disorders (rheumatoid arthritis, systemic lupus erythematosus, Crohn’s disease, multiple sclerosis), immune system-mediated (psoriasis), transplant rejection, thrombosis, cancer, allergic well others. Immunoconjugates comprised antibody linked chemotherapeutic agent or source(s) radiation discussed cancer. treatment cancer includes both hematologic malignancies solid tumors. each identified along its precise mechanism action, clinical use, adverse effects.

参考文章(240)
Russell L Dedrick, Patricia Walicke, Marvin Garovoy, Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody. Transplant Immunology. ,vol. 9, pp. 181- 186 ,(2002) , 10.1016/S0966-3274(02)00029-1
Mark S. Berger, Lance H. Leopold, James A. Dowell, Joan M. Korth-Bradley, Matthew L. Sherman, Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse. Investigational New Drugs. ,vol. 20, pp. 395- 406 ,(2002) , 10.1023/A:1020658028082
Joan Albanell, Jordi Codony, Ana Rovira, Begoña Mellado, Pere Gascón, Mechanism of Action of Anti-Her2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2c4 Advances in Experimental Medicine and Biology. ,vol. 532, pp. 253- 268 ,(2003) , 10.1007/978-1-4615-0081-0_21
Interstitial pneumonitis related to rituximab therapy. The New England Journal of Medicine. ,vol. 348, pp. 2690- ,(2003) , 10.1056/NEJM200306263482619
D. Przepiorka, N. A. Kernan, C. Ippoliti, E. B. Papadopoulos, S. Giralt, I. Khouri, J.-G. Lu, J. Gajewski, A. Durett, K. Cleary, R. Champlin, B. S. Andersson, S. Light, Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease Blood. ,vol. 95, pp. 83- 89 ,(2000) , 10.1182/BLOOD.V95.1.83.001K18_83_89
Paul Carter, Improving the efficacy of antibody-based cancer therapies Nature Reviews Cancer. ,vol. 1, pp. 118- 129 ,(2001) , 10.1038/35101072
Napoleone Ferrara, Kenneth J Hillan, Hans-Peter Gerber, William Novotny, None, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nature Reviews Drug Discovery. ,vol. 3, pp. 391- 400 ,(2004) , 10.1038/NRD1381
Omalizumab for asthma. The New England Journal of Medicine. ,vol. 355, pp. 1281- ,(2006) , 10.1056/NEJMC061914
Infliximab for ulcerative colitis. The New England Journal of Medicine. ,vol. 354, pp. 1424- 1426 ,(2006) , 10.1056/NEJMC053667